You are viewing: Latin America Oral Proteins & Peptides Market analysis

The Latin America Oral Proteins & Peptides Market was valued at $339.5 Million in 2025 and projected to reach to $650.7 Million by 2030, representing a compound annual growth rate of 13.9%. Latin America's oral proteins & peptides market is positioned for sustained expansion through 2030, driven by escalating chronic disease burden and modernization of healthcare infrastructure across the region.

Latin America Oral Proteins & Peptides Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Latin America Oral Proteins & Peptides Market Trends and Insights

  • Latin America's market growth is driven by increasing prevalence of chronic diseases, rising healthcare expenditure, and growing adoption of advanced pharmaceutical formulations across the region.
  • The 13.9% compound annual growth rate reflects Latin America's strengthening position in the global oral therapeutics landscape, supported by improving regulatory frameworks and expanding distribution networks. Latin America's oral proteins & peptides sector benefits from demographic shifts and enhanced patient awareness regarding protein-based therapeutics.
  • Throughout the forecast period to 2030, Latin America is expected to witness accelerated market penetration as biopharmaceutical companies invest in regional manufacturing and clinical development.
  • Latin America's market dynamics are shaped by both established economies and emerging markets within the region, creating diverse opportunities for innovation and market entry across multiple therapeutic categories..

Key Market Statistics

  • CAGR (2025-2030) 13.9% CAGR
  • Market Size, 2025 ~USD 339.5 Million
  • Forecast, 2030 ~USD 650.7 Million
  • Geography Latin America

Latin America Oral Proteins & Peptides Market Overview

Strong Regional Growth Trajectory :

Latin America's oral proteins & peptides market is expanding at 13.9% CAGR, significantly outpacing global average expectations, with market value growing from USD 339.5 million in 2025 to USD 650.7 million by 2030.

Chronic Disease Prevalence Driving Demand :

Rising incidence of diabetes, cardiovascular diseases, and metabolic disorders across Latin America is accelerating demand for advanced oral protein and peptide-based therapeutic solutions.

Increased Healthcare Investment :

Growing healthcare expenditure and government initiatives to improve pharmaceutical access in Latin American countries are creating favorable conditions for oral protein formulation adoption.

Advanced Formulation Adoption :

Latin American healthcare providers and patients are increasingly embracing innovative oral delivery technologies and bioavailability-enhanced peptide formulations for improved treatment outcomes.

Latin America Oral Proteins & Peptides Market Dynamics

  • Brazil and Mexico are emerging as key growth engines, supported by rising middle-class populations with improved healthcare access and pharmaceutical awareness.
  • Regulatory frameworks are gradually aligning with international standards, facilitating faster market entry for innovative oral peptide therapies.
  • Investment in biotechnology and pharmaceutical manufacturing capabilities within Latin America is expected to strengthen local supply chains and reduce dependency on imports, further accelerating market penetration and affordability..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • SANOFI
  • Pfizer Inc.
  • NOVARTIS

    Key Takeaways

    • Latin America's oral proteins & peptides market is valued at USD 339.5 million in 2025 and will nearly double to USD 650.7 million by 2030.
    • Latin America demonstrates a 13.9% CAGR, outpacing many mature markets and reflecting strong regional demand for innovative protein therapeutics.
    • Latin America's growth is fueled by rising chronic disease burden, improved healthcare infrastructure, and increased biopharmaceutical investment in the region.
    • Latin America's market expansion is supported by regulatory harmonization efforts and expanding patient access to oral peptide-based treatments across diverse therapeutic areas.

    Oral Proteins & Peptides Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment OBESITY & OVERWEIGHT (Therapeutic Area)
    Forecast Period 2025–2030
    Growth Rate CAGR of 22.1% from 2025 to 2030
    Largest Segment TABLETS (Formulation)
    Market Size Base Year (Billions) ~USD 8.84 (2025)
    Revenue Forecast (Billions) ~USD 24 (2030)
    Segments Covered Molecule, Drug Class, Formulation, Therapeutic Area, End User

    Latin America Oral Proteins & Peptides Market Report Segmentation

    5 segment dimensions are covered across the global market.

    By Molecule

    • Calcitonin
    • Linaclotide
    • Other Molecules
    • Plecanatide
    • Semaglutide
    • Trofinetide
    • Voclosporin

    By Drug Class

    • Cgrp Receptor Antagonists
    • Cnis
    • Gc-C Agonists
    • Glp-1 Receptor Agonists
    • Gpe
    • Other Drug Classes

    By Formulation

    • Capsules
    • Oral Solutions
    • Tablets

    By Therapeutic Area

    • Cns Disorders
    • Diabetes
    • Gastroenterology
    • Genetic Disorders
    • Nephrology
    • Obesity & Overweight
    • Other Therapeutic Areas

    By End User

    • Home Care Settings
    • Hospitals & Specialty Clinics
    • Long-Term Care Facilities

    Target Audience

    • Pharmaceutical Manufacturers : Need market sizing and growth forecasts for Latin America to guide R&D investment, manufacturing capacity planning, and commercial launch strategies for oral protein and peptide products.
    • Healthcare Investors & PE Firms : Require validated market data and regional growth projections to assess investment opportunities, evaluate portfolio companies, and identify high-potential acquisition targets in Latin America's biotech sector.
    • Healthcare Providers & Hospital Networks : Need insights into emerging oral peptide therapies and market trends to inform procurement decisions, treatment protocols, and patient care strategies across Latin American healthcare systems.
    • Regulatory & Government Bodies : Utilize market intelligence to develop pharmaceutical policies, healthcare infrastructure investments, and regulatory frameworks that support innovation and access to advanced oral protein therapies in Latin America.
    • Market Consultants & Business Strategists : Require comprehensive regional data to support client advisory services, competitive benchmarking, and strategic planning initiatives for companies operating in or entering Latin America's pharmaceutical market.

    Key Companies in the Latin America Oral Proteins & Peptides Market

    CompanyHQOwnershipStrongest segments
    NOVO NORDISK A/SDenmarkPublic CompanyObesity and Diabetes Care – GLP-1 injectables (including Wegovy),Obesity and Diabetes Care – oral GLP-1 and other diabetes therapies,Rare Disease – rare blood and endocrine disorders,
    ABBVIE INC.United StatesPublic CompanyImmunology (Skyrizi, Rinvoq and related autoimmune/inflammatory),Oncology/Hematology (Imbruvica, Venclexta, Elahere, Epkinly, Emrelis),Neuroscience & CNS (Vraylar, Duodopa, Vyalev and related),
    PFIZER INC.IndiaPublic CompanyInternal medicine (CV, respiratory, gastro, multivitamins, neuroscience, women’s health),Vaccines,Injectables and anti-infectives,
    BAUSCH HEALTH COMPANIES INC.CanadaPublic CompanyBausch + Lomb (eye health),Salix (gastroenterology and hepatology),Solta Medical (aesthetic medical devices),
    ACADIA PHARMACEUTICALS INC.United StatesPublic CompanyNUPLAZID (Parkinson’s disease psychosis),DAYBUE / trofinetide (Rett syndrome),Pipeline and other revenues,
    AURINIA PHARMACEUTICALS INC.CanadaPublic CompanyLUPKYNIS (voclosporin) for lupus nephritis,Other pipeline and collaboration revenue (including aritinercept-related),
    MERCK & CO., INC.United StatesPublic CompanyOncology (Keytruda, Keytruda Qlex, Welireg, ADC collaborations, Lynparza co-commercialization),Vaccines (Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23),Hospital & Specialty (Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/Verquvo, Ohtuvayre),
    SWK HOLDINGSUnited StatesPrivate Investment FirmHealthcare venture debt (biopharma, medtech, diagnostics, life science tools),Healthcare services and HIT lending,Technology and SaaS venture debt (non-healthcare),
    ENTERA BIO LTD.IsraelPublic CompanyEB613 – oral teriparatide (osteoporosis, stress fractures),EB612 – hypoparathyroidism peptide replacement,EB618 – GLP-1/glucagon dual agonist (obesity, metabolic, fibrotic),
    ASTRAZENECA PLCUnited KingdomPublic CompanyOncology (Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Imjudo, others),Cardiovascular, Renal & Metabolism (Farxiga/Forxiga, Brilinta/Brilique, Crestor, diabetes combinations),Respiratory & Immunology (Symbicort, Fasenra, Tezspire, Breztri, Airsupra, others),

    NOVO NORDISK A/S

    Novo Nordisk A/S is a Danish pharmaceutical company founded in 1923 with 67,900 employees. Operating as a public company, it is a major player in the global pharmaceutical industry.

    ABBVIE INC.

    AbbVie Inc. is a United States-based public pharmaceutical company established in 2012 with 57,000 employees. The company operates in the pharmaceutical sector with significant global operations.

    PFIZER INC.

    Pfizer Inc. operates as a public company in India with 1,244 employees, having been established in 1950. The company is engaged in pharmaceutical operations in the Indian market.

    BAUSCH HEALTH COMPANIES INC.

    Bausch Health Companies Inc. is a Canadian public company with 20,300 employees operating in the pharmaceutical and healthcare sectors.

    ACADIA PHARMACEUTICALS INC.

    Acadia Pharmaceuticals Inc. is a United States-based public pharmaceutical company founded in 1993 with 797 employees. The company focuses on pharmaceutical development and commercialization.

    AURINIA PHARMACEUTICALS INC.

    Aurinia Pharmaceuticals Inc. is a Canadian public company established in 1993 with 128 employees. The company operates in the pharmaceutical sector.

    MERCK & CO., INC.

    Merck & Co., Inc. is a United States-based public pharmaceutical company founded in 1891 with 74,000 employees. It is one of the world's largest pharmaceutical manufacturers.

    SWK HOLDINGS

    SWK Holdings is a United States-based private investment firm founded in 1996 with 9 employees.

    ENTERA BIO LTD.

    Entera Bio Ltd. is an Israeli public company founded in 2009 with 21 employees operating in the pharmaceutical sector.

    ASTRAZENECA PLC

    AstraZeneca PLC is a United Kingdom-based public pharmaceutical company founded in 1992 with 96,100 employees. It is a major global pharmaceutical manufacturer.

    Latin America vs. other regions

    HowLatin America compares to the other 3 regional blocs covered in this market.

    North America
    ~USD 5880.7 Million · 24.1% wtd CAGR ·
    Europe
    ~USD 3180.3 Million · 21% wtd CAGR ·
    Asia Pacific
    ~USD 1135 Million · 17.2% wtd CAGR ·

    Countries within Latin America - compare and drill down

    Country2025 size (native)
    BrazilUSD 348.9 Million
    MexicoUSD 88 Million
    Rest Of Latin AmericaUSD 213.7 Million

    Country market size visualization

    Brazil
    USD 348.9 Million
    Mexico
    USD 88 Million
    Rest Of Latin America
    USD 213.7 Million

    Reasons to Buy this Report

    • Market Size & Growth Validation : Comprehensive data confirming Latin America's 13.9% CAGR and USD 311.2 million market expansion opportunity through 2030, enabling confident investment and expansion planning decisions.
    • Country-Level Intelligence : Detailed market segmentation across Brazil, Mexico, and Rest of Latin America, providing granular insights into regional variations, competitive dynamics, and localized growth opportunities.
    • Strategic Market Positioning : Actionable insights on chronic disease prevalence, healthcare spending patterns, and regulatory environments specific to Latin America to inform market entry and product development strategies.
    • Competitive Landscape Analysis : Understanding of regional market dynamics, key players, and emerging competitors in Latin America's oral proteins & peptides sector to identify partnership and acquisition opportunities.
    • Forecast-Driven Planning : Five-year projections through 2030 enable long-term strategic planning, resource allocation, and revenue forecasting for pharmaceutical companies, investors, and healthcare stakeholders in Latin America.

    Frequently asked questions

    What is the current market size of oral proteins & peptides in Latin America?

    Latin America's oral proteins & peptides market is estimated at USD 339.5 million in 2025, with expectations to grow significantly through 2030.

    What is the projected market size for Latin America by 2030?

    Latin America's oral proteins & peptides market is forecasted to reach USD 650.7 million by 2030, representing substantial regional growth.

    What is the CAGR for the oral proteins & peptides market in Latin America?

    Latin America's oral proteins & peptides market is expected to grow at a compound annual growth rate of 13.9% from 2025 to 2030.

    What factors are driving growth in Latin America's oral proteins & peptides market?

    Latin America's market growth is driven by increasing chronic disease prevalence, rising healthcare spending, regulatory improvements, and growing biopharmaceutical investment in the region.

    How does Latin America's market growth compare to global trends?

    Latin America's 13.9% CAGR is competitive within the global market context, reflecting strong regional adoption of oral protein and peptide therapeutics.

    RESEARCH METHODOLOGY

    This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global oral proteins and peptides market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

    Secondary Research

    Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the oral proteins and peptides market. The secondary sources used for this study include the World Health Organization (WHO), National Institutes of Health (NIH), United States Food and Drug Administration (US FDA), European Medicines Agency (EMA), National Center for Biotechnology Information (NCBI), BioPharm International, International Diabetes Federation, ScienceDirect, ClinicalTrials.gov, PubMed, European Federation of Pharmaceutical Industries and Associations (EFPIA), European Lead Factory (ELF), India Brand Equity Foundation (IBEF), UK Research Partnership Investment Fund (UKRPIF), Pharmaceutical Research and Manufacturers of America (PhRMA), Eurostat, and Factiva; research journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; and trade, business, professional associations. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

    Primary Research

    Extensive primary research was conducted after acquiring basic knowledge about the global oral proteins and peptides market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical and biotechnology companies, CROs, CMOs, and academic & research institutes, and experts from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. These interviews were conducted across six major regions, including the Asia Pacific, North America, Europe, Latin America, the Middle East, and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

    The following is a breakdown of the primary respondents:

    Oral Proteins and Peptides Market

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The bottom-up approach was used to estimate and validate the total size of the oral proteins and peptides market. These methods were also extensively utilized to estimate the size of various subsegments within the market. The research methodology used to estimate the market size includes the following:

    • The list of approved oral proteins and peptides was identified through extensive secondary and primary research.
    • The oral protein and peptide products in the pipeline were identified from clinical trial registries and from secondary and primary research related to peptide and protein therapeutics.
    • The revenues generated from these oral proteins and peptides were determined through annual reports and secondary sources (including paid databases).
    • The products were categorized according to market segments. Percentage shares and splits were calculated based on revenue contributions for each segment. This information was validated using secondary sources and insights from industry experts.
    • All assumptions, approaches, and individual shares/revenue estimates were validated through expert interviews.

    Global Oral Proteins and Peptides Market Size: Bottom-up Approach

    Oral Proteins and Peptides Market

    Data Triangulation

    After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    Oral proteins and peptides are therapeutic drugs made from proteins or peptides (short chains of amino acids) that are meant to be taken by mouth. These biologically active molecules are designed to treat a variety of medical conditions, including chronic diseases such as diabetes, hormonal disorders, and autoimmune disorders.

    Stakeholders

    • Pharmaceutical & biotechnology companies
    • Hospitals
    • Specialty clinics
    • Long-term care facilities
    • Patient advocacy organizations
    • Academic researchers and government research organizations
    • Private research institutes
    • Contract manufacturing organizations (CMOs)
    • Contract research organizations (CROs)
    • Venture capitalists

    Report Objectives

    • To define, describe, and forecast the oral proteins and peptides market based on molecule, drug class, therapeutic area, formulation, end user, and region
    • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall oral proteins and peptides market
    • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
    • To profile the key players in the oral proteins and peptides market and comprehensively analyze their product portfolios, market positions, and core competencies
    • To track and analyze competitive developments in the oral proteins and peptides market, such as acquisitions, product launches/approvals, expansions, agreements, partnerships, and collaborations
    • To benchmark players within the oral proteins and peptides market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business strategy and product strategy

     

    Get the Full Oral Proteins & Peptides Market Report

    Full forecast, segment splits, and company analysis for all Oral Proteins & Peptides Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status